Chong Kun Dang Pharmaceutical (XKRX:185750) Interest Expense : ₩-9,079 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Chong Kun Dang Pharmaceutical's interest expense for the three months ended in Mar. 2024 was ₩ -2,078 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-9,079 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Chong Kun Dang Pharmaceutical's Operating Income for the three months ended in Mar. 2024 was ₩ 30,832 Mil. Chong Kun Dang Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was ₩ -2,078 Mil. Chong Kun Dang Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 was 14.84. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chong Kun Dang Pharmaceutical Interest Expense Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Interest Expense Chart

Chong Kun Dang Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-3,150.52

-3,870.92

-4,029.89

-6,846.93

-9,270.97

Chong Kun Dang Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-2,269.85	-2,284.04	-2,286.52	-2,430.57	-2,078.00

Chong Kun Dang Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-9,079 Mil.

Chong Kun Dang Pharmaceutical (XKRX:185750) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Chong Kun Dang Pharmaceutical's Interest Expense for the three months ended in Mar. 2024 was ₩-2,078 Mil. Its Operating Income for the three months ended in Mar. 2024 was ₩30,832 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was ₩41,213 Mil.

Chong Kun Dang Pharmaceutical's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	30832.321	/	-2078.003
	=	14.84

The higher the ratio, the stronger the company's financial strength is.

Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Interest Expense

Traded in Other Exchanges

N/A

Address

368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756

Website

http://chongkundang.en.ec21.com

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines